Sugi Predict

Sugi Predict / Compounds / SCHEMBL6739008

SCHEMBL6739008

SCHEMBL6739008

Sc1nnc2c(n1)[nH]c1ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.65
▸ SMN1; SMN2 Q16637 5/20 0.56
▸ NPC1 O15118 4/20 0.56
▸ RAB9A P51151 4/20 0.56
▸ TP53 P04637 2/20 0.56
▸ CASP1 P29466 2/20 0.56
▸ MAPK10 P53779 2/20 0.56
▸ CASP7 P55210 2/20 0.56
▸ POLB P06746 1/20 0.56
▸ CNR2 P34972 8/20 0.52
▸ ALDH1A1 P00352 2/20 0.51
▸ KMT2A Q03164 3/20 0.50
▸ LMNA P02545 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ MAPK1 P28482 3/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29506282 1.00 MAPT (0.65) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL903237 0.79 MAPT (0.65) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL28389941 0.77 GAA (0.65) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL29506279 0.77 GAA (0.43) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL28392626 0.77 GAA (0.43) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL29506319 0.77 GAA (0.65) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL28393245 0.77 MEN1 (0.47) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL29506305 0.77 ALDH1A1 (0.47) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL14092954 0.77 MAPT (0.40) MAPTPOLBCNR2ALDH1A1KMT2A
SCHEMBL28391228 0.77 ALDH1A1 (0.47) MAPTSMN1; SMN2NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11564919-B1 Small molecule inhibitors for treatment of alpha viruses NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2023-01-31 — — US disclosed
CN-110964018-B Indole derivative and application thereof 华侨大学 2022-03-11 — — CN disclosed
US-20210134398-A1 Combinatorial Chemistry Computational System and Enhanced Selection Method NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-05-06 — — US disclosed
US-20210134398-A1 Combinatorial Chemistry Computational System and Enhanced Selection Method NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-05-06 — — US disclosed
CN-110964018-A Indole derivative and application thereof 华侨大学 2020-04-07 — — CN disclosed
US-9447103-B2 Inauhzin analogues that induce P53, inhibit cell growth, and have antitumor activity INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2016-09-20 — — US disclosed
US-20150197522-A1 INAUHZIN ANALOGUES THAT INDUCE P53, INHIBIT CELL GROWTH, AND HAVE ANTITUMOR ACTIVITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) 2015-07-16 — — US disclosed
US-20140378451-A1 Cannabinoid-2-Receptor Agonists ISIS INNOVATION LIMITED (GB) 2014-12-25 — — US disclosed
US-20140378451-A1 Cannabinoid-2-Receptor Agonists ISIS INNOVATION LIMITED (GB) 2014-12-25 — — US disclosed
US-20140378451-A1 Cannabinoid-2-Receptor Agonists ISIS INNOVATION LIMITED (GB) 2014-12-25 — — US disclosed
EP-2766022-A1 CANNABINOID-2-RECEPTOR AGONISTS Isis Innovation Limited (GB) 2014-08-20 — — EP disclosed
WO-2013041859-A1 CANNABINOID-2-RECEPTOR AGONISTS ISIS INNOVATION LIMITED (GB) 2013-03-28 — — WO disclosed
WO-2013041859-A1 CANNABINOID-2-RECEPTOR AGONISTS ISIS INNOVATION LIMITED (GB) 2013-03-28 — — WO disclosed
US-20040127499-A1 Compounds, compositions and methods for preventing and treating pestivirus infection and associated diseases PEVEAR DANIEL C 2004-07-01 — — US disclosed
US-20030176431-A1 Compounds, compositions and methods for preventing and treating pestivirus infection and associated diseases PEVEAR DANIEL C 2003-09-18 — — US disclosed
US-6541472-B1 3-thio-5H-1,2,4-triazino(5,6-b) indole derivatives VIROPHARMA INCORPORATED 2003-04-01 — — US disclosed
US-5830894-A USING A TRIAZINOINDOLE COMPOUND VIROPHARMA INCORPORATED (US) 1998-11-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11564919-B1 Small molecule inhibitors for treatment of alpha viruses ERN2, SPINT2, EIF2AK2 MAPT 34/4885SMN1; SMN2 474/4885NPC1 290/4885
US-20030176431-A1 Compounds, compositions and methods for preventing and treating pestivirus infection and associated diseases ZC3HAV1, MAVS, HAVCR2 MAPT 1994/4885SMN1; SMN2 1383/4885NPC1 468/4885
US-20140378451-A1 Cannabinoid-2-Receptor Agonists CNR2, CNR1, GPR18 MAPT 2084/4885SMN1; SMN2 3246/4885NPC1 711/4885
US-20040127499-A1 Compounds, compositions and methods for preventing and treating pestivirus infection and associated diseases ZC3HAV1, MAVS, HAVCR2 MAPT 1994/4885SMN1; SMN2 1383/4885NPC1 468/4885
US-20150197522-A1 INAUHZIN ANALOGUES THAT INDUCE P53, INHIBIT CELL GROWTH, AND HAVE ANTITUMOR ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NOP58 MAPT 3443/4885SMN1; SMN2 4475/4885NPC1 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.